Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharma's Other Operating Expense for the
three
months ended in Jun. 2026 was 円0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was 円934.28 Mil.
Oncolys BioPharma's quarterly Other Operating Expense
increased
from Dec. 2025 (円0.00 Mil) to Mar. 2026 (円423.81 Mil) but then
declined
from Mar. 2026 (円423.81 Mil) to Jun. 2026 (円0.00 Mil).
Oncolys BioPharma's annual Other Operating Expense
declined
from Dec. 2023 (円1,960.59 Mil) to Dec. 2024 (円1,712.79 Mil) but then
increased
from Dec. 2024 (円1,712.79 Mil) to Dec. 2025 (円2,052.61 Mil).
Oncolys BioPharma Other Operating Expense Related Terms
Oncolys BioPharma Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円934.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of 円934.28 Mil mean?
Oncolys BioPharma (TSE:4588) has a Other Operating Expense of 円934.28 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's Other Operating Expense too high?
Oncolys BioPharma's current Other Operating Expense is 円934.28 Mil. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Other Operating Expense compare to VRTX and REGN?
Oncolys BioPharma's Other Operating Expense of 円934.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current Other Operating Expense is 円934.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円355.30, compared to a current price of 円3,420.00 — trading 862.6% above its estimated fair value. The current Other Operating Expense is 円934.28 Mil. Oncolys BioPharma's overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Other Operating Expense is 円934.28 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円3,420.00 is trading 862.6% above its estimated GF Value™ of 円355.30.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Other Operating Expense: 円934.28 Mil
GF Value™: 円355.30 vs. price of 円3,420.00 (862.6% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
